XML 22 R11.htm IDEA: XBRL DOCUMENT v3.22.2.2

Intangible Assets

3 Months Ended

Sep. 30, 2022

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

4. Intangible Assets

The Company’s intangible assets consist of intellectual property acquired from LAT Pharma, Inc. and are amortized over their estimated useful lives.

The following is a summary of the intangible assets as of September 30, 2022 and June 30, 2022:

Schedule of intangible assets
		September 30, 2022				June 30, 2022
Intellectual Property		$	2,293,770			$	2,293,770
Less Accumulated Amortization			(1,484,642	)			(1,427,298	)
Intellectual Property, Net		$	809,128			$	866,472

Amortization expense was $57,344 in each of the three-month periods ended September 30, 2022 and 2021. The Company amortizes intellectual property over the expected original useful lives of 10 years.

Estimated future amortization expense is as follows:

Schedule of future amortization expense
Year ending June 30, 2023 (Remaining nine months)		$	172,033
2024			229,377
2025			229,377
2026			178,341
		$	809,128

X

- References

No definition available.

+ Details

Name:	us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The entire disclosure for all or part of the information related to intangible assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-URI https://asc.fasb.org/subtopic&trid=2144471

+ Details

Name:	us-gaap_IntangibleAssetsDisclosureTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration